Kidney Failure Attributed to Focal Segmental Glomerulosclerosis: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden
Sparsentan vs Irbesartan in Patients With Focal Segmental Glomerulosclerosis (FSGS): Results From the Phase 3 DUPLEX Trial
FILSPARI (sparsentan) – 2-Year Results from the Phase 3 DUPLEX Study Published in the NEJM
Proteinuria and kidney survival in focal segmental glomerulosclerosis (FSGS) or immunoglobulin A nephropathy (IgAN): A NEPTUNE analysis
The Humanistic Burden of Rare Kidney Diseases: Understanding the Impact of Focal Segmental Glomerulosclerosis (FSGS) and Immunoglobulin A Nephropathy (IgAN) on Patients and Caregivers Study (HONUS): Results for FSGS in the United States (US)
EPPIK (Phase 2 Study): Treatment in Pediatric Patients With Proteinuric Glomerular Diseases
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis
Phase 2 DUET Study Published in the Journal of the American Society of Nephrology
Implications of Complete Proteinuria Remission at Any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial
FILSPARI (sparsentan) – Effect on Proteinuria in Focal Segmental Glomerulosclerosis
FILSPARI (sparsentan) – Pediatric Patients in Sparsentan FSGS Studies
FILSPARI (sparsentan) – Hyperkalemia
Effect of Multiple Doses of Sparsentan on the Single-Dose Pharmacokinetics of Dapagliflozin: An Open-Label Drug–Drug Interaction Study in Healthy Adults